News

AeroVironment's Anticipated Earnings: What to Expect from Analysts

AeroVironment's Anticipated Earnings: What to Expect from Analysts

AeroVironment's Upcoming Earnings and Analyst Predictions

AeroVironment, Inc (NASDAQ: AVAV) is gearing up for its second-quarter earnings release, which is eagerly awaited by investors and market analysts alike. This anticipated report will provide insights into the company's financial performance and future potential.

Analysts' Revenue Expectations

Analysts are predicting a significant rise in quarterly earnings for AeroVironment, estimating earnings per share to be 79 cents, a noticeable increase from 47 cents per share during the same period last year. Additionally, the consensus estimate suggests that the company's revenue could reach approximately $465.63 million, a significant jump from $188.46 million reported a year earlier. These figures highlight the growth trajectory of the business in the growing market for unmanned aerial systems.

Recent Contract Wins

In a significant boost for the company, AeroVironment unveiled the securing of an $874 million five-year IDIQ contract with the U.S. Army. This deal underscores the company's capabilities and reliability in providing unmanned aerial systems and counter-UAS systems, further positioning AeroVironment as a competitive player in the defense industry.

Stock Performance Insights

Following the announcement of the new contract, AeroVironment’s stock saw an increase of 1.5%, closing at $282.47. This positive shift reflects investor confidence likely fueled by the company's robust prospects and upcoming earnings report.

Analysts' Ratings Overview

Recent assessments from reputable analysts bolster the optimistic outlook for AeroVironment. Here’s a brief overview of their ratings:

  • RBC Capital analyst Kevin Liu has an Outperform rating but revised the price target downward from $440 to $400, showcasing a 64% accuracy rate.
  • BTIG analyst Andre Madrid maintains a Buy rating with a target of $415, backed by a 70% accuracy rate.
  • JMP Securities analyst Trevor Walsh has rated the stock as Market Outperform, raising the price target from $325 to $400, achieving an impressive accuracy of 87%.
  • Baird analyst Peter Arment continues with an Outperform rating, boosting the price target from $267 to $350, boasting an 85% accuracy rate.
  • Raymond James analyst Brian Gesuale holds a Strong Buy rating with an increased target from $300 to $348, achieving a 75% accuracy rate.

Conclusion: What Lies Ahead for AeroVironment?

As AeroVironment prepares to present its earnings, investor curiosity remains high regarding the company's performance and outlook. With analysts optimistic about revenue growth and a solid pipeline of contracts, the future appears bright for AeroVironment, Inc. With ongoing developments in unmanned technology, it will be interesting to see how these factors affect the reported outcomes in the upcoming earnings call.

Frequently Asked Questions

When will AeroVironment announce its earnings?

AeroVironment will release its earnings for the second quarter after the market closes on a specified date.

What are analysts predicting for AeroVironment's earnings?

Analysts expect earnings to rise to 79 cents per share, with significant revenue growth anticipated.

What recent contracts has AeroVironment secured?

The company recently announced an $874 million contract with the U.S. Army for unmanned aerial systems.

How did AeroVironment's stock perform recently?

The stock saw a rise of 1.5%, closing at $282.47, indicating positive investor sentiment.

What do analysts think about AeroVironment's future?

Analysts have maintained optimistic ratings, with several adjusting price targets upward based on the company's performance and contract wins.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 269

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
China's 15th Plan: Key Moves in the Capital Markets

Updated Category News Views 127

Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...

Continue Reading
CStone's CS2009: A Leap in Cancer Treatment Validated

Updated Category News Views 59

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

Continue Reading
NOTHING NINE's Global Ambitions: Paris Show's Impact

Updated Category News Views 83

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Continue Reading
Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Updated Category News Views 13

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Continue Reading
Superteam Wheels Rides Into Spain with RACEIT Deal

Updated Category News Views 63

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Continue Reading
Zinzino Eyes European Market With New Botanical Line

Updated Category News Views 98

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

Continue Reading
HCLTech Partners with Rapidus on Semiconductor Future

Updated Category News Views 81

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

Continue Reading
ASICS and University of Michigan Launch Innovation Lab

Updated Category News Views 88

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 412

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

TuHURA Biosciences Advances Phase 3 Trial for Cancer Treatment

Updated Category News Views 229

TuHURA Biosciences Moves Forward with Phase 3 Trial TuHURA Biosciences, Inc. (NASDAQ: HURA) is making substantial strides in the field of cancer immunotherapy. The company is geared up to launch its Phase 3 accelerated approval trial of IFx-2.0, a promising adjunctive therapy in combination with Keytruda (pembrolizumab), targeting advanced and metastatic Merkel cell...

Continue Reading
Fiserv, Inc. Lawsuit: Investors Can Fight Back Against Losses

Updated Category News Views 198

Introduction to the Class Action Lawsuit In recent news, numerous investors in Fiserv, Inc. are being alerted to an important opportunity. A class action lawsuit has been initiated targeting Fiserv, a prominent figure in the financial services tech sector. This situation arises from allegations of significant financial losses endured by shareholders due to the Company's...

Continue Reading
Exploring Humana's Decreased Short Interest and Market Impact

Updated Category News Views 104

Understanding Humana's Short Interest Trends Recently, Humana Inc (NYSE: HUM) has reported a notable decline in its short percent of float, decreasing by 6.3% since the previous report. As of now, the company has approximately 4.30 million shares sold short, which constitutes about 3.57% of the total shares available for trading. Based on the current trading volumes, it...

Continue Reading
Innovative Restaurant Launch Featuring AI Robots Opens Soon

Updated Category News Views 344

AI-Driven Restaurant Opening at Walmart Supercenter In an exciting development for the dining industry, Richtech Robotics Inc. (NASDAQ: RR), a leader in AI-driven service robots, has joined forces with Ghost Kitchens America to unveil their latest One Kitchen restaurant. This location, situated within a Walmart Supercenter, is marking a significant milestone as it becomes...

Continue Reading
Choosing the Perfect MySmile Teeth Whitening Solution for You

Updated Category News Views 82

Your Guide to MySmile Teeth Whitening Products Achieving a whiter, brighter smile is easier than ever with MySmile's effective teeth whitening solutions. MySmile offers a range of products tailored to fit different lifestyles; whether you're interested in an all-in-one kit, convenient whitening strips, or one-step solutions, the right product is just a choice away. Let's...

Continue Reading